Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce R Schackman

Showing results (31-40 of 221) with videos related to

Pageof 23
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2006
Overcoming policy and financing barriers to integrated buprenorphine and HIV primary careBruce R Schackman, Joseph O Merrill, Dennis McCarty, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 19, 2010
Expanded HIV screening in the United States: what will it cost government discretionary and entitlement programs? A budget impact analysisErika G Martin, A David Paltiel, Rochelle P Walensky, et al.
Journal of the American Geriatrics Society|July 27, 2006
Response to commentary by Dr. Oliver and colleagues on hip protectorsLisa A Honkanen, Bruce R Schackman, Alvin I Mushlin, et al.
Journal of the American Geriatrics Society|January 28, 2005
A cost-benefit analysis of external hip protectors in the nursing home settingLisa A Honkanen, Bruce R Schackman, Alvin I Mushlin, et al.
Journal of Public Health Management and Practice : JPHMP|December 21, 2020
Addressing Barriers to On-site HIV and HCV Testing Services in Methadone Maintenance Treatment Programs in the United States: Findings From a National Multisite Qualitative StudyCzarina N Behrends, Shashi N Kapadia, Bruce R Schackman, et al.
Health Services Research|February 22, 2019
Will converting naloxone to over-the-counter status increase pharmacy sales?Sean M Murphy, Jake R Morgan, Philip J Jeng, et al.
Pharmacoeconomics|April 6, 2004
How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions?Bruce R Schackman, Heather Taffet Gold, Patricia W Stone, et al.
Medical Care|June 3, 2021
Hepatitis C Treatment by Nonspecialist Providers in the Direct-acting Antiviral EraShashi N Kapadia, Phyllis Johnson, Kristen M Marks, et al.
Substance Abuse Treatment, Prevention, and Policy|August 4, 2007
Does higher cost mean better quality? evidence from highly-regarded adolescent drug treatment programsBruce R Schackman, Erick G Rojas, Jeremy Gans, et al.
Journal of General Internal Medicine|October 7, 2011
Inappropriate medication in a national sample of US elderly patients receiving home health careYuhua Bao, Huibo Shao, Tara F Bishop, et al.
Pageof 23

Showing results (31-40 of 221) with videos related to

Sort By:
Pageof 23
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2006
Overcoming policy and financing barriers to integrated buprenorphine and HIV primary careBruce R Schackman, Joseph O Merrill, Dennis McCarty, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 19, 2010
Expanded HIV screening in the United States: what will it cost government discretionary and entitlement programs? A budget impact analysisErika G Martin, A David Paltiel, Rochelle P Walensky, et al.
Journal of the American Geriatrics Society|July 27, 2006
Response to commentary by Dr. Oliver and colleagues on hip protectorsLisa A Honkanen, Bruce R Schackman, Alvin I Mushlin, et al.
Journal of the American Geriatrics Society|January 28, 2005
A cost-benefit analysis of external hip protectors in the nursing home settingLisa A Honkanen, Bruce R Schackman, Alvin I Mushlin, et al.
Journal of Public Health Management and Practice : JPHMP|December 21, 2020
Addressing Barriers to On-site HIV and HCV Testing Services in Methadone Maintenance Treatment Programs in the United States: Findings From a National Multisite Qualitative StudyCzarina N Behrends, Shashi N Kapadia, Bruce R Schackman, et al.
Health Services Research|February 22, 2019
Will converting naloxone to over-the-counter status increase pharmacy sales?Sean M Murphy, Jake R Morgan, Philip J Jeng, et al.
Pharmacoeconomics|April 6, 2004
How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions?Bruce R Schackman, Heather Taffet Gold, Patricia W Stone, et al.
Medical Care|June 3, 2021
Hepatitis C Treatment by Nonspecialist Providers in the Direct-acting Antiviral EraShashi N Kapadia, Phyllis Johnson, Kristen M Marks, et al.
Substance Abuse Treatment, Prevention, and Policy|August 4, 2007
Does higher cost mean better quality? evidence from highly-regarded adolescent drug treatment programsBruce R Schackman, Erick G Rojas, Jeremy Gans, et al.
Journal of General Internal Medicine|October 7, 2011
Inappropriate medication in a national sample of US elderly patients receiving home health careYuhua Bao, Huibo Shao, Tara F Bishop, et al.
Pageof 23